Anti-Hu CD184 PE-Cy™5

Anti-Hu CD184 PE-Cy™5
Regulatory status
RUO
Antigen
CD184
Clone
12G5
Format
PE-Cy™5
Reactivity
Human, Non-human primates
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
100 tests
T8-146-T100
Out of stock
Variant
0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG2a kappa
Specificity
The mouse monoclonal antibody 12G5 recognizes CD184, a 45 kDa G-protein-linked CXC chemokine receptor widely expressed on blood and tissue cells.
Workshop
HLDA VII: WS Code 70204
Application
FC (QC tested)
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Reactivity
Human, Non-human primates
Immunogen
CP-MAC-infected Sup-T1 cells
Other names
CXCR4, LAP3, LCR1, HM89, fusin, SDF1R
Preparation
The purified antibody is conjugated with tandem dye PE-Cy™5 under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
Licence note
Cy™ and CyDye™ are registered trademarks of GE Healthcare.

Product specific references:

Koopman G, Mortier D, Hofman S, Koutsoukos M, Bogers WM, Wahren B, Voss G, Heeney JL: Acute-phase CD4+ T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian-human immunodeficiency virus strain 89.6p-infected macaques. J Gen Virol. 2009 Apr;90(Pt 4):915-26.
PubMed
Campioni D, Zauli G, Gambetti S, Campo G, Cuneo A, Ferrari R, Secchiero P: In vitro characterization of circulating endothelial progenitor cells isolated from patients with acute coronary syndrome. PLoS One. 2013;8(2):e56377.
PubMed
Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012 Apr 26;119(17):3917-24.
PubMed
Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J: Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med. 2009 Aug 31;206(9):1957-70.
PubMed
Variant
100 tests
T8-146-T100
Out of stock
Variant
0.1 mg
11-261-C100
In stock